SK288038B6 - Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection - Google Patents

Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection Download PDF

Info

Publication number
SK288038B6
SK288038B6 SK1710-2000A SK17102000A SK288038B6 SK 288038 B6 SK288038 B6 SK 288038B6 SK 17102000 A SK17102000 A SK 17102000A SK 288038 B6 SK288038 B6 SK 288038B6
Authority
SK
Slovakia
Prior art keywords
weeks
patients
interferon alpha
hcv
treatment
Prior art date
Application number
SK1710-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK17102000A3 (sk
Inventor
Janice K Albrecht
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK288038(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SK17102000A3 publication Critical patent/SK17102000A3/sk
Publication of SK288038B6 publication Critical patent/SK288038B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SK1710-2000A 1998-05-15 1999-05-13 Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection SK288038B6 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7956698A 1998-05-15 1998-05-15
PCT/US1999/007037 WO1999059621A1 (en) 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection

Publications (2)

Publication Number Publication Date
SK17102000A3 SK17102000A3 (sk) 2001-05-10
SK288038B6 true SK288038B6 (en) 2013-01-02

Family

ID=22151354

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1710-2000A SK288038B6 (en) 1998-05-15 1999-05-13 Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection

Country Status (23)

Country Link
EP (3) EP1213029A1 (es)
JP (2) JP5281726B2 (es)
KR (1) KR100694345B1 (es)
CN (1) CN1230198C (es)
AR (1) AR019551A1 (es)
AT (1) ATE216591T1 (es)
AU (2) AU766597B2 (es)
BR (1) BR9910505A (es)
CA (1) CA2331823A1 (es)
CZ (1) CZ300540B6 (es)
DE (1) DE69901321T2 (es)
DK (1) DK0956861T3 (es)
ES (1) ES2172288T3 (es)
HK (1) HK1021131A1 (es)
HU (1) HU230432B1 (es)
IL (3) IL139220A0 (es)
MY (1) MY129244A (es)
NO (1) NO330715B1 (es)
NZ (1) NZ507621A (es)
PT (1) PT956861E (es)
SK (1) SK288038B6 (es)
TW (1) TWI277424B (es)
WO (1) WO1999059621A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037110A2 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
JP2003523957A (ja) * 1999-12-23 2003-08-12 アイシーエヌ・ファーマシューティカルズ・インコーポレイテッド 組成物、並びにｌ−ヌクレオシド、ｌ−ヌクレオチドおよびそれらのアナログの製造法
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
JP2003530847A (ja) * 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
AU2002213343A1 (en) * 2000-10-18 2002-04-29 Schering Corporation Ribavirin-pegylated interferon alfa HCV combination therapy
CA2466228A1 (en) * 2001-11-09 2003-08-07 Biomedicines, Inc. Method for treating diseases with omega interferon
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
CN104163841B (zh) 2002-06-28 2016-08-24 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
BR0316363A (pt) 2002-11-15 2005-10-04 Idenix Cayman Ltd Nucleosìdeos 2'-ramificado e mutação de flaviviridae
AU2004224575A1 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
WO2004110392A2 (en) * 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
MXPA05011170A (es) * 2003-04-17 2005-12-14 Ares Trading Sa Interferon beta en el sindrome respiratorio agudo severo.
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
JP2006527268A (ja) * 2003-06-09 2006-11-30 ゲノム インスティチュート オブ シンガポール 臨床的に認められた抗ウイルス剤を用いるｓａｒｓコロナウイルス感染の阻害
RU2371195C2 (ru) * 2003-08-13 2009-10-27 Говард Дж. Смит Энд Эссошиэйтс Пти Лтд Способ лечения вирусных инфекций
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
ES2725457T3 (es) 2004-09-14 2019-09-24 Gilead Pharmasset Llc Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados
TW201424733A (zh) * 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
ZA200806310B (en) * 2006-01-09 2009-12-30 Romark Lab Lc Viral hepatitis treatment
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101820887A (zh) 2007-07-25 2010-09-01 拜奥雷克斯治疗公司 干扰素控释药品以及使用相同药品治疗hcv感染
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
AU2009329917B2 (en) 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
CN102458470B (zh) 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PE20130151A1 (es) 2010-03-31 2013-02-21 Gilead Pharmasset Llc Sintesis estereoselectiva de activos que contienen fosforo
US20130225483A1 (en) * 2010-10-05 2013-08-29 Claudio Avila New Treatments of Hepatitis C Virus Infection
TW201242974A (en) 2010-11-30 2012-11-01 Gilead Pharmasset Llc Compounds
BR112013022391A2 (pt) * 2011-03-02 2018-01-16 SCHENTAG Jerome composições, métodos de tratamento e diagnóstico para o tratamento de esteatose hepática apenas ou em combinação com uma infecção pelo vírus da hepatite c e uso dessas composições
MD4589C1 (ro) 2011-09-16 2019-03-31 Gilead Pharmasset Llc Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EA029081B9 (ru) 2013-01-31 2018-09-28 Джилид Фармассет Ллс Комбинированный состав двух противовирусных соединений
CA2921160C (en) 2013-08-27 2021-04-13 Gilead Pharmasset Llc Combination formulation of two antiviral compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
PT730470E (pt) 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
ATE262920T1 (de) * 1995-11-02 2004-04-15 Schering Corp Kontinuierliche, niedrigdosierte zytokine- infusionstherapie
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CA2298543A1 (en) 1997-08-13 1999-02-25 James Barry Loading and release of water-insoluble drugs
DK1136075T3 (da) * 1997-09-21 2003-04-28 Schering Corp Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion

Also Published As

Publication number Publication date
SK17102000A3 (sk) 2001-05-10
JP5281726B2 (ja) 2013-09-04
DE69901321D1 (de) 2002-05-29
EP0956861B1 (en) 2002-04-24
CZ20004177A3 (cs) 2001-04-11
NZ507621A (en) 2002-11-26
NO330715B1 (no) 2011-06-20
AR019551A1 (es) 2002-02-27
HU230432B1 (hu) 2016-06-28
ES2172288T3 (es) 2002-09-16
JP2011173898A (ja) 2011-09-08
DK0956861T3 (da) 2002-07-01
CZ300540B6 (cs) 2009-06-10
IL139220A0 (en) 2001-11-25
HK1021131A1 (en) 2000-06-02
DE69901321T2 (de) 2002-12-12
NO20005755D0 (no) 2000-11-14
CN1230198C (zh) 2005-12-07
BR9910505A (pt) 2001-01-02
AU2005220271B9 (en) 2010-12-09
CN1309568A (zh) 2001-08-22
PT956861E (pt) 2002-08-30
HUP0103423A2 (hu) 2002-01-28
AU2005220271B2 (en) 2005-11-03
TWI277424B (en) 2007-04-01
IL207259A0 (en) 2010-12-30
KR20010043624A (ko) 2001-05-25
IL139220A (en) 2013-02-28
EP1213029A1 (en) 2002-06-12
JP2002515453A (ja) 2002-05-28
WO1999059621A1 (en) 1999-11-25
IL207259A (en) 2016-08-31
MY129244A (en) 2007-03-30
AU3860099A (en) 1999-12-06
EP2305287A1 (en) 2011-04-06
EP0956861A1 (en) 1999-11-17
ATE216591T1 (de) 2002-05-15
AU2005220271A1 (en) 2005-11-03
AU2005220271B8 (en) 2010-11-18
AU766597B2 (en) 2003-10-16
CA2331823A1 (en) 1999-11-25
NO20005755L (no) 2001-01-12
HUP0103423A3 (en) 2003-11-28
KR100694345B1 (ko) 2007-03-12

Similar Documents

Publication Publication Date Title
SK288038B6 (en) Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection
US6472373B1 (en) Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
TW568787B (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US20020127203A1 (en) Ribavirin-pegylated interferon alfa HCV combination therapy
US6824768B2 (en) Ribavirin-pegylated interferon alfa induction HCV combination therapy
WO2000037110A2 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
WO2000037097A1 (en) Ribavirin-interferon alfa induction hcv combination therapy
MXPA00011198A (es) Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han recibido tratamiento antiviral que tienen infeccion por hepatitis c cronica
MXPA01006161A (es) Terapia de combinacion para el virus de la hepatitis c por induccion de ribavirina-interferon alfa pegilado
CZ2000788A3 (cs) Použití ribavirinu pro výrobu farmaceutických prostředků, použití interferonů alfa pro výrobu farmaceutických prostředků a farmaceutické výrobky
MXPA98007284A (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
AU2005218024A1 (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, NJ, US

Effective date: 20121108

MK4A Expiry of patent

Expiry date: 20190513